

Original Article

Changing trends in Uropathogens and their Antimicrobial sensitivity pattern

Ahmed Abu Saleh, Syed Shaukat Ahmed, Moniruzzaman Ahmed, Abu Naser Ibne Sattar, Md.Ruhul Amin Miah

Department of Microbiology and Immunology, Bangabandhu Sheikh Mujib Medical University, Dhaka.

Abstract

In order to monitor changes in the etiologic bacterial agents and as well as antimicrobial resistance of urinary pathogens between five years period and over several years, urinary culture and sensitivity result of patients attending the outpatient departments of Bangabandhu Sheikh Mujib Medical University (BSMMU) in 2003 and in 2008 were analyzed retrospectively. In 2003 and 2008, 668 and 715 cultures respectively were reviewed. The frequency of *Escherichia coli* dropped significantly in the outpatient clinics from 60.02% to 51.75%. The frequency of *Klebsiella spp* increased considerably. The frequency of *Enterobacter spp*, *Enterococci spp* and *Acenatobacter* collectively increased from 25.15 to 31.04 ($p<0.0001$). A significant rise in the resistance of *Escherichia coli* to gentamicin and ciprofloxacin ($p<0.0001$) was documented. Urinary pathogens also demonstrated increased resistance to Nalidixic acid and Cefotaxime. In contrast Amoxicillin, Cephadrine ($p<0.0001$), Cotrimoxazole ($p<0.0001$), Mecilinam ($p<0.0001$), Ceftriaxone ($p<0.0001$). Nitrofurantoin, Ceftazidime, Cefuroxime, Amikacin and Netilmicin showed consistent sensitivity. Ciprofloxacin showed increase in resistance against Enterococci and Klebsiella. The changing etiologic agents of urinary tract infections and the increasing resistance of organisms clearly dictate regular monitoring and modification of empirical therapy are required.

Key words: Urinary tract infection, Antimicrobial resistance pattern, Changing pattern

Introduction:

In community and hospital settings the etiology of UTIs and the antimicrobial susceptibility of uropathogens have been changing over the years.⁴⁻⁵ Factors such as the changing patient population, extensive use and misuse of Antimicrobial agents could all contribute to changes in the bacterial profile of UTI.⁶

Knowledge of the antimicrobial resistance patterns of common uropathogens according to local epidemiology is essential for providing clinically appropriate, cost effective therapy for UTI.⁷⁻⁸

Objective of the study was to assess the change in the bacterial profile and pattern of antibiotic resistance of Bacteria associated with urinary tract infections between 2003 and 2008.

Methods

A retrospective study was conducted in the department of Microbiology and Immunology, BSMMU. One thousand three hundred eighty three culture positive results were taken

✉ Correspondence:

- Professor Ahmed Abu Saleh
- Department of Microbiology & Immunology
- Bangabandhu Sheikh Mujib Medical University, Dhaka.
- Email: aasaleh@gamil.com

for study. Of them 668 were in year 2003 and 715 patients in 2008. The distribution of bacterial isolates and their in vitro susceptibility to antibiotics was evaluated.

Results

Sex distribution of present study clearly dictates Female dominance. Study also shows slightly increased male patient in 2008 in comparison to year 2003. (Table-I)

Table-I: Distribution of urine specimens from outpatient clinics and the hospital according to sex

| Sex | 2003 | 2008 | P value |
|--------|-------------|-------------|---------|
| Male | 30 (4.6%) | 50 (7.2%) | NS |
| Female | 619 (95.4%) | 640 (92.8%) | NS |
| Total | 649 (100%) | 690 (100%) | |

NS: not significant

Escherichia coli was the most frequently isolated pathogen in both occasions, *Enterobacter spp.* was the second. Frequency *E. coli* declined over time (60.02% in 2003 and 51.75% in 2008), with higher percentage of *Enterobacter spp.*, *Enterococci spp.*, *Klebsiella spp.* and *Acinetobacter spp.* Isolation rate of *Proteus*, *Pseudomonas* and *Streptococci* remain almost unchanged. (Table-2)

Table-2. Frequency of pathogens causing UTI in patient attending OPD of BSMMU in 2003 and 2008.

| Rank order | Organism | Number of Isolate n (%) | |
|------------|----------------------|-------------------------|-------------------|
| | | 2003 | 2008 |
| 1 | <i>E. coli</i> | 401 (60.02%) | 370 (51.75%) |
| 2 | <i>Enterococci</i> | 76 (11.38%) | 95 (13.29%) |
| 3 | <i>Enterobacter</i> | 76 (11.38%) | 98 (13.70%) |
| 4 | <i>Klebsiella</i> | 65 (9.73%) | 101 (14.10%) |
| 5 | <i>Acinetobacter</i> | 16 (2.39%) | 29 (4.05%) |
| 6 | <i>Pseudomonas</i> | 27 (4.04%) | 10 (1.40%) |
| 7 | <i>Proteus</i> | 04 (0.59%) | 07 (0.98%) |
| 8 | <i>Streptococci</i> | 02 (0.29%) | 05 (0.70%) |
| 9 | CNS* | 01 (0.15%) | 00 (00.00%) |
| | Total growth | 668 (100%) | 715 (100%) |

*CNS : Coagulase Negative Staphylococcus, Figure in parenthesis indicate percentages

There was also a considerable change in resistance patterns to antibiotics. An upward trend in the resistance of *E. coli* to Ciproloxacin (16.21% vs 20.94%), to Gentamicin (62.0% vs 45.21%), to Cefotaxime(71.0% vs 53.0%), was observed in 2003 and 2008 respectively. Amikacin, Netilmicin and Imipenem showed consistent sensitivity in both the years.

Amoxicillin, Cephadrine, Cotrimoxazole, Mecillinam showed an increased sensitivity against *E. coli* in 2008 than in 2003.

Ciprofloxacin (41.25% vs 26.20%), Micellinam (21.05% vs 11.55%), Genatamicin (15.79% vs 9.45%) showed increased resistance against *Enterococci* in 2008 than in 2003. *Enterobacter* isolates were highly resistant to Amoxicillin, Cephadrine, Ciprofloxacin and Gentamicin. It also showed increased resistance against Amikacin and Mecillinam (Table-3). *Klebsiella* showed antimicrobial sensitivity almost similar to *Enterobacter* except having good sensitivity to Amikacin and Netilmicin.

Table 3: Distribution of the bacterial susceptibility to antibiotics

| Drug | 2003 | | 2008 | | 2003 | | 2008 | |
|----------------|----------------|--------------------|---------------------|-------------------|----------------|--------------------|---------------------|-------------------|
| | <i>E. coli</i> | <i>Enterococci</i> | <i>Enterobacter</i> | <i>Klebsiella</i> | <i>E. coli</i> | <i>Enterococci</i> | <i>Enterobacter</i> | <i>Klebsiella</i> |
| Amoxicillin | 23 (5.74%) | 36 (9.89%) | 40 (52.63%) | 51 (53.68%) | 01 (1.31%) | 3 (3.05%) | 00 (00%) | 03 (2.97%) |
| Cephadrine | 16 (3.99%) | 39 (10.45%) | 09 (11.84%) | 11 (11.55%) | 04 (5.26%) | 6 (6.23%) | 06 (9.23%) | 07 (6.93%) |
| Cotrimoxazole | 79 (19.7%) | 101 (27.30%) | 12 (15.79%) | 18 (18.90%) | 11 (14.47%) | 10 (10.23%) | 10 (15.38%) | 04 (3.96%) |
| Ciprofloxacin | 84 (20.94%) | 60 (16.21%) | 31 (41.25%) | 25 (26.20%) | 13 (17.10%) | 11 (11.57%) | 35 (53.85%) | 18 (18.73%) |
| Nitrofurantoin | 292 (72.82%) | 289 (78.02%) | 58 (76.31%) | 63 (66.15%) | 21 (27.63%) | 38 (38.77%) | 16 (24.61%) | 29 (28.71%) |
| Nalidixic Acid | 45 (11.22%) | 31 (8.34%) | 06 (7.89%) | 11 (11.55%) | 12 (15.79%) | 19 (19.38%) | 14 (21.53%) | 13 (12.87%) |
| Mecillinam | 173 (43.14%) | 247 (67.08%) | 16 (21.05%) | 11 (11.55%) | 15 (19.73%) | 37 (37.35%) | 15 (23.07%) | 36 (35.45%) |
| Ceftriaxone | 200 (49.88%) | 289 (78.21%) | 44 (58.40%) | 63 (66.15%) | 18 (23.68%) | 36 (36.73%) | 54 (83.07%) | 53 (52.48%) |
| Gentamicin | 249 (62.0%) | 167 (45.21%) | 12 (15.79%) | 09 (9.45%) | 14 (18.42%) | 12 (12.24%) | 27 (41.53%) | 30 (29.70%) |
| Cefotaxime | 285 (71.0%) | 196 (53.0%) | 08 (11.11%) | 15 (15.75%) | 07 (17.5%) | NT | 40 (61.54%) | 38 (37.62%) |
| Ceftazidime | 301 (75.01%) | 260 (70.20%) | 13 (16.67%) | 29 (30.45%) | 07 (17.5%) | 22 (22.44%) | 38 (58.46%) | 29 (28.71%) |
| Cefuroxime | 261 (67.0%) | 229 (61.82%) | 04 (22.22%) | NT | 06 (15%) | 17 (17.34%) | 29 (44.61%) | 38 (37.62%) |
| Amikacin | 341 (85.12%) | 304 (82.21%) | 16 (44.44%) | 31 (32.55%) | 30 (75%) | 74 (75.51%) | 58 (89.23%) | 87 (86.14%) |
| Imipenem | 401 (100%) | 370 (100%) | 76 (100%) | 95 (100%) | 40 (100%) | 97 (98.9%) | 65 (100%) | 98 (97.02%) |
| Netilmicin | 333 (83.08%) | 301 (81.25%) | 25 (33.33%) | 43 (45.20%) | 14 (35%) | 55 (56.12%) | 65 (100%) | 70 (69.30%) |
| Piperaciline | NT | NT | 04 (22.22%) | NT | NT | NT | NT | NT |
| Linezolid | NT | NT | 49 (64.44%) | NT | NT | NT | NT | NT |

NT: Not tested

Discussion

UTIs are the most common nosocomial infections, with similar pattern of infection reported in many other countries. They are often associated with significant mortality and

morbidity. Understanding of etiology and antimicrobials susceptibility of major bacteria that cause urinary tract infections will provide essential information regarding the selection of antibiotic therapy for infected patients in the OPD of BSMMU. The sex distribution of patients in the present study is consistent with that of other reported studies, showing a predominance of females with UTI^{20,21}. However, the female to male ratio shows a progressive reduction from 2003 to 2008. It is possible that the higher proportion of male patients attending outpatient department of BSMMU.

Although the etiology of UTI has been changing over the past few years²², *Escherichia coli* remains the most common urinary pathogen.^{9,10,11} However, our study showed that its frequency in outpatient specimens has decreased significantly in the last five years, whereas *Enterobacter* spp. and other gram-negative bacteria increased in frequency in this group which is consistent with other studies^{12,13,14,23,24}.

A high percentage of ciprofloxacin-resistant strains was found as compared with recent publications on nosocomial isolates recovered from various clinical specimens.^{15,16} gentamicin and cefotaxime exhibited poorer activity toward *Enterobacter* and *Klebsiella*. These data are different from those reported by Blondeau *et al.*¹⁷. In recent years gentamicin and cefuroxime have been used extensively in our hospitals may be a clue for poor activity of the two drugs.

Data presented in this study indicate that antibiotics commonly used in UTIs are losing effectiveness but species distribution and their susceptibility to antibiotics are changing in general all around the world. It requires regular monitoring in order to make reliable information available for optimal empirical therapy for patients with UTIs.

As discussed previously a high percentage of ciprofloxacin resistance *E. coli* was observed in this surveillance study. Such resistance is reported by many other studies.^{18,19} The resistance rate to ciprofloxacin vary from one country to another and depends on local antibiotic prescription practice. Increased resistance in the ciprofloxacin against *E. coli* may reflect the overuse of quinolones for treatment of UTI.

The widespread uses of antibiotics and changes in the spectrum of urinary pathogens have led to a rise in the resistance of urinary pathogens. The association between

antimicrobial drug consumption and selection of resistant bacterial strains is widely acknowledged. The trends observed in the last five years in the two populations in this study show important epidemiological changes, reflected also in the rise in antibiotic resistance of these strains. Cefuroxime, gentamicin and ciprofloxacin are losing effectiveness to treat UTI in the community.

The slow but persistent and significant decrease in sensitivity of gram-negative bacteria to ciprofloxacin and gentamicin is alarming because these antibiotics have been one of the best options for treatment of UTI.

In conclusion the result presented in this study confirm that there is a trend in change of bacterial agents causing UTI and increasing bacterial resistance against commonly used antibiotics.

References

1. □Tice AD. Short course therapy of acute cystitis: a brief review of therapeutic strategies. *J Antimicrobial Chemo* 1999, 43: 85–93.
2. □Clarridge JE, Johnson JR & Pezzlo MT. *Cumitech 2B Laboratory Diagnosis of Urinary Tract Infections*, (Weissfeld AS Ed.). Washington, DC 1998. *Am Soc Microbiol.* 596-622
3. □ Sussman M. Urinary tract infections. In *Topley & Wilson's Microbiology and Microbial Infections*, edited by Collier L, Balows A & Sussman M. 9th edition, Arnold, London 1998, pp. 601–21.
4. □ New HC. Urinary tract infections. *Am J Med* 1996, 100 (Suppl.4A): S63-70.
5. □ Jones RN. Impact of changing pathogens and antimicrobial susceptibility pattern in treatment of serious infections in hospitalized patients. *Am J Med* 1996, 100 (Suppl.6A): S3-12.
6. □Brosnema DA, Adams JR, Roem CV and Pallares R. Bacterial pathogens isolated from patients with blood stream infections. *Antimicrobial agents and Chemotherapy.* 1998, 42: 1762-70.
7. □Ferry S, Burman LG & Holm SE. Clinical and bacteriological effects of therapy of urinary tract infection in primary health care: relation to in vitro sensitivity testing. *Scand J Infect Dis* 1988, 20: 535–44.
8. □ Henry D, Ellison W, Sullivan J, Mansfield DL, Magner DJ, Dorr MB et al. Treatment of community acquired acute

- uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi-Center UTI Study Group. *Antimicrobial Agents and Chemotherapy* 1998, 42: 2262–6.
9. □ Tice AD. Short course therapy of acute cystitis: a brief review of therapeutic strategies. *J Antimicrobial Chemo* 1999, 43: 85–93.
 10. □ Schaeffer AJ. Urinary tract infections in the elderly. *European Urology* 1991, 19 (Suppl.1): 2-6.
 11. Boscia JA, Kaye D. Asymptomatic bacteriuria in the elderly. *Infectious Disease Clinics of North America* 1987,22(3): 153-58
 12. Gruneberg RN. Changes in urinary pathogens and their antibiotic sensitivities 1971–1992. *J Antimicrobial Chemotherapy* 1994, 33 (Suppl. A): 1–8.
 13. □ Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R & Verhoef J. Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. *Antonie van Leeuwenhoek* 2000, 77: 147–52.
 14. Cunney RJ, McNally RM, McNamara EM, Al-Ansari N & Smyth EG. Susceptibility of urinary pathogens in a Dublin teaching hospital. *Irish J Med Science* 1992, 161: 623–5.
 15. Jones RN, Kugler KC, Pfaller MA, Winokur PL & The SENTRY Surveillance Group, North America. Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program, 1997. *Diag Microbiol Infect Dis* 1999, 35: 55–63.
 16. Palucha A, Mikiewicz B, Hryniewicz W & Gniadkowski M. Concurrent outbreaks of extended-spectrum β -lactamase producing organisms of the family Enterobacteriaceae in a Warsaw hospital. *J Antimicrob Chemo* 1999, 44: 489–99.
 17. Blondeau, JM, Laskowski R, Borsos S & The Canadian Afermenter Study Group. In- vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. *J Antimicrob Chemo* 1999, 44: 545–8.
 18. □ Amyes SG, Baird DR, Crook DW, Gillespie SH., Howard AJ *et al*. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens. *J Antimicrob Chemo* 1994, 34: 639–48.
 19. □ Dromigny JA, Nabeth P, Perrier G, Claude JD. Distribution and susceptibility of bacterial urinary tract infections in Dakar, Senegal. *Int J Antimicrob Agents* 2002, 20(5): 339-347.
 20. □ Neu HC. Urinary tract infections. *American Journal of Medicine* 1992, 92: (Suppl. 4A): 63-70.
 21. □ Sobel JD, Kaye D. Host factors in the pathogenesis of urinary tract infections. *Am J Med* 1984, 76 (Suppl. 5A): 122-130.
 22. □ Gupta K, Hooton TM, Wobbe CL, Stamm WE. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. *Int J Antimicrob Agents*. 1999, 11(3-4): 305-308.
 23. □ Groneberg RN. Changes in urinary pathogens and their antibiotic sensitivities, 1971-1992. *J Antimicrob Chemo* 1994, 33 (Suppl. A): 1-8.
 24. □ Bronsema DA, Adams JR, Pallares R, Wenzel RP. Secular trends in rates and etiology of nosocomial urinary tract infections at a university hospital. *Journal of Urology* 1993, 150: 414-416.